Disclosure statement
No potential conflict of interest was reported by the authors.
Additional information
Funding
This study was partially supported by Italian Ministry of Health – Ricerca Corrente Annual Program 2024.
Leukemia & Lymphoma
Volume 64, 2023 - Issue 10
Letters to the Editor
Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment
Domenico Pennaa Hematology Unit, Azienda Unitа Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy;b Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalyCorrespondence[email protected]
https://orcid.org/0000-0002-3102-422XView further author information
https://orcid.org/0000-0002-3102-422XView further author information, , & ![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})